Colorectal clinical trials: what is on the horizon?

被引：1

作者：

Ahn, Daniel H. ^{[1
]}

Goldberg, Richard M. ^{[1
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Med Oncol, 460 W 10th Ave, Columbus, OH 43210 USA

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 04期

关键词：

colorectal cancer; immunotherapy; next-generation sequencing; targeted therapy; WILD-TYPE KRAS; MICROSATELLITE INSTABILITY; BRAF MUTATION; OPEN-LABEL; ACQUIRED-RESISTANCE; GENE AMPLIFICATION; CANCER STATISTICS; PLUS IRINOTECAN; RAS MUTATIONS; SOLID TUMORS;

D O I：

10.2217/fon.15.327

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

引用

页码：525 / 531

页数：7

共 65 条

[41] Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival
Osako, T
Miyahara, M
Uchino, S
Inomata, M
Kitano, S
Kobayashi, M
[J]. ONCOLOGY, 1998, 55 (06) : 548 - 555
[42] Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, Anirudh
Sun, Chong
Huang, Sidong
Di Nicolantonio, Federica
Salazar, Ramon
Zecchin, Davide
Beijersbergen, Roderick L.
Bardelli, Alberto
Bernards, Rene
[J]. NATURE, 2012, 483 (7387) : 100 - U146
[43] Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Price, Timothy J.
Peeters, Marc
Kim, Tae Won
Li, Jin
Cascinu, Stefano
Ruff, Paul
Suresh, Atilli Satya
Thomas, Anne
Tjulandin, Sergei
Zhang, Kathy
Murugappan, Swaminathan
Sidhu, Roger
[J]. LANCET ONCOLOGY, 2014, 15 (06) : 569 - 579
[44] Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
Price, Timothy J.
Hardingham, Jennifer E.
Lee, Chee K.
Weickhardt, Andrew
Townsend, Amanda R.
Wrin, Joseph W.
Chua, Ann
Shivasami, Aravind
Cummins, Michelle M.
Murone, Carmel
Tebbutt, Niall C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : 2675 - 2682
[45] REOVIRUS INFECTIONS IN HUMAN VOLUNTEERS
ROSEN, L
SPICKARD, A
EVANS, HE
[J]. AMERICAN JOURNAL OF HYGIENE, 1963, 77 (01): : 29 - &
[46] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Saltz, Leonard B.
Clarke, Stephen
Diaz-Rubio, Eduardo
Scheithauer, Werner
Figer, Arie
Wong, Ralph
Koski, Sheryl
Lichinitser, Mikhail
Yang, Tsai-Shen
Rivera, Fernando
Couture, Felix
Sirzen, Florin
Cassidy, Jim
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2013 - 2019
[47] Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
Samowitz, WS
Sweeney, C
Herrick, J
Albertsen, H
Levin, TR
Murtaugh, MA
Wolff, RK
Slattery, ML
[J]. CANCER RESEARCH, 2005, 65 (14) : 6063 - 6070
[48] Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
[49] Cancer Statistics, 2014
Siegel, Rebecca
Ma, Jiemin
Zou, Zhaohui
Jemal, Ahmedin
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2014, 64 (01) : 9 - 29
[50] Smyrk TC, 2001, CANCER, V91, P2417, DOI 10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.3.CO

← 1 2 3 4 5 6 7 →